A - Human Necessities – 61 – K
Patent
A - Human Necessities
61
K
A61K 39/395 (2006.01) A61K 45/06 (2006.01) A61K 47/48 (2006.01) A61P 37/00 (2006.01) C07K 16/28 (2006.01)
Patent
CA 2467242
The present invention relates to methods for the treatment of immunological disorders other than cancer, comprising administering proteins characterized by their ability to bind to CD30 and exert a cytostatic or cytotoxic effect on an activated lymphocyte. Such proteins include monoclonal antibodies AC10 and HeFi1, AC10 and HeFi-1 derivatives, and antibodies that compete with AC10 and HeFi-1 for binding to CD30. Other such proteins include multivalent anti-CD30 antibodies and anti-CD30 antibodies conjugated to cytotoxic agents. Treatment modalities with the antibodies of the invention are also provided.
La présente invention concerne des procédés de traitement des troubles immunologiques autres que le cancer, qui consistent à administrer des protéines caractérisées par leur capacité de se lier à CD30 et d'exercer un effet cytostatique ou cytotoxique sur un lymphocyte activé. Ces protéines comprennent des anticorps monoclonaux AC10 et HeFi1, des dérivés d'AC10 et de HeFi-1, et des anticorps qui entrent en compétition avec AC10 et HeFi-1 pour se lier à CD30. D'autres protéines de ce type comprennent des anticorps anti-CD30 multivalents et des anticorps anti-CD30, conjugués à des agents cytotoxiques. L'invention concerne aussi des modalités de traitement avec les anticorps de l'invention.
Doronina Svetlana
Klussman Kerry
Law Che-Leung
Senter Peter
Toki Brian
Osler Hoskin & Harcourt Llp
Seattle Genetics Inc.
LandOfFree
Treatment of immunological disorders using anti-cd30 antibodies does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Treatment of immunological disorders using anti-cd30 antibodies, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Treatment of immunological disorders using anti-cd30 antibodies will most certainly appreciate the feedback.
Profile ID: LFCA-PAI-O-1446007